Article
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Cancer biology & therapy - 1 Aug 2013
Al-Marrawi Mhd Yaser, Saroya Bikramajit Singh, Brennan Matthew C, Yang Zhaohai, Dykes Thomas M, El-Deiry Wafik S
Abstract excerpt
Sorafenib, the first agent developed to target BRAF mutant melanoma, is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer, and is currently in clinical trials for thyroid, lung and brain cancer. Colorectal cancer with V600E BRAF mutation has shown relative resistance to standard chemotherapy regimens, as well as lack of efficacy to vemurafenib in clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.